This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Wednesday's Health Winners & Losers

Shares of drug developer Progen Industries (PGLA) jumped more than 160% after the company announced positive results on an experimental cancer drug.

In clinical trials, patients who had cancerous tumors removed from their livers went 76% longer before tumor recurrence when given the drug, dubbed PI-88, compared with patients not on the treatment. Shares were up $4.75 to $7.70.

Shares of cancer drug developer Celgene (CELG - Get Report) sank 2.7% to $55.99 after the company said that Barr Pharmaceuticals (BRL) is looking to market thalidomide, a generic version of Celgene's blood cancer drug Thalomid.

Barr intends to market its version as a treatment for a skin condition associated with leprosy, the first indication Celgene's branded version of the drug received. Thalomid was more recently approved to treat the blood cancer multiple myeloma, a condition with a much larger market than that of leprosy in the U.S.

Vertex Pharmaceuticals (VRTX - Get Report) fell 1.5% to $38.80 after the company released results from an interim safety analysis of its hepatitis C drug telaprevir.

While 9% of patients receiving the drug in clinical trials discontinued treatment due to side effects, 65 out of 74 patients had undetectable levels of the virus after treatment, Vertex says. The company received a $15 million milestone payment from its partner, Johnson & Johnson (JNJ - Get Report) unit Janssen Pharmaceutica based on the trial results.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
CELG $116.21 0.01%
JNJ $101.99 -0.42%
POZN $6.70 0.37%
VRTX $125.20 0.12%
PGLA $0.14 1.45%


DOW 18,274.93 -10.81 -0.06%
S&P 500 2,129.38 -1.44 -0.07%
NASDAQ 5,097.9440 +7.15 0.14%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs